Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901944 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL3064079 | 0.92 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL3086513 | 0.91 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL3075799 | 0.88 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL3070314 | 0.88 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL4349674 | 0.87 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL13010134 | 0.86 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL3069698 | 0.85 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL3075919 | 0.85 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL4354902 | 0.85 | CHEK1 (0.86) | CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2582374-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | Afraxis, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2504011-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | Afraxis, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2485733-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | Afraxis, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011159945-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20100317715-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS HOLDINGS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100317715-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS HOLDINGS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100317715-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS HOLDINGS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317715-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | GRM5, GRIK5, PAK5 | CHEK1 2193/4885KCNH2 3486/4885 |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN2, MAPT, PSEN1 | CHEK1 3969/4885KCNH2 4161/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | CHEK1 4368/4885KCNH2 1599/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | CHEK1 4201/4885KCNH2 2528/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | CHEK1 4242/4885KCNH2 1409/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | CHEK1 2923/4885KCNH2 1186/4885 |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | CHAT, PSEN2, PAK2 | CHEK1 1084/4885KCNH2 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.